Truist Financial’s ProQR Therapeutics PRQR Stock Holding History

Truist Financial’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$16.2K	Hold	10,000	–	–	﹤0.01%	2780
2025 Q4	$20.2K	Hold	10,000	–	–	﹤0.01%	2747
2025 Q3	$21.3K	Hold	10,000	–	–	﹤0.01%	2701
2025 Q2	$20.4K	Hold	10,000	–	–	﹤0.01%	2578
2025 Q1	$13.3K	Hold	10,000	–	–	﹤0.01%	2531
2024 Q4	$26.5K	Hold	10,000	–	–	﹤0.01%	2495
2024 Q3	$18.2K	Hold	10,000	–	–	﹤0.01%	2472
2024 Q2	$16.6K	Hold	10,000	–	–	﹤0.01%	2626
2024 Q1	$22.9K	Hold	10,000	–	–	﹤0.01%	2598
2023 Q4	$19.8K	Hold	10,000	–	–	﹤0.01%	2614
2023 Q3	$13K	Hold	10,000	–	–	﹤0.01%	2570
2023 Q2	$16.2K	Buy	+10,000	New	+$19.5K	﹤0.01%	2548

Other funds holding PRQR

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PFM

Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Truist Financial's PRQR Position: Q1 2026 in Review

Truist Financial held its ProQR Therapeutics (PRQR) position steady in Q1 2026 at 10,000 shares worth $16.2K. The position accounts for ﹤0.01% of the portfolio, ranked #2780.

Truist Financial first reported a position in PRQR in Q2 2023 and has held it in 12 quarters since. The position peaked at $26.5K in Q4 2024. 69 funds tracked by Wall St. Rank hold PRQR as of Q1 2026.

Truist Financial held 10,000 shares of ProQR Therapeutics worth $16.2K as of Q1 2026.
Truist Financial left its ProQR Therapeutics share count unchanged in Q1 2026.
ProQR Therapeutics made up ﹤0.01% of Truist Financial's portfolio in Q1 2026, its #2780 holding.
Truist Financial first reported a position in ProQR Therapeutics in Q2 2023 and has held it in 12 quarters since.
Truist Financial's ProQR Therapeutics position peaked at $26.5K in Q4 2024.
69 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q1 2026.

Based on Truist Financial's 13F filing for Q1 2026, filed 27 Apr 2026.